sdAb 1E2

A single-domain humanized antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

sdAb 1E2 is a single domain humanized antibody developed using phage display approach targeting SARS-CoV-2 (Chi et al., 2020).

Link	Tested on	Impact factor	Notes	Publication date
Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain Spike protein Biophysical assay In vitro Antibody	in vitro biophysical assay; Vero E6 cells; SARS-CoV-2 strain with GISAID ID of EPI_ISL_402123	12.12	The single domain antibody prepared using phage display approach with the SARS-CoV-2 spike protein RBD was shown to potently inhibit the live or pseudotyped virus. It was experimentally fused with human IgG1 Fc-domain, which maintained or further increased its neutralizing activity.	Sep/10/2020